BioRegenx, Inc.
BRGX
$0.0115
-$0.0005-4.17%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -20.09% | -31.41% | 154.50% | 319.99% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.09% | -31.41% | 154.50% | 319.99% | -- |
| Cost of Revenue | -34.41% | -38.02% | 174.65% | 377.64% | -- |
| Gross Profit | -13.02% | -28.25% | 145.66% | 294.85% | -- |
| SG&A Expenses | -55.59% | 14.03% | 104.72% | 2,974.80% | -- |
| Depreciation & Amortization | -- | -- | 18,954.24% | 9,427.12% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.04% | 30.36% | 150.84% | 1,946.58% | -- |
| Operating Income | 41.88% | -92.16% | -148.86% | -3,693.76% | -- |
| Income Before Tax | -209.20% | -540.39% | -182.47% | -2,315.53% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -209.20% | -540.39% | -182.47% | -2,315.53% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -209.20% | -540.39% | -182.47% | -2,315.53% | -- |
| EBIT | 41.88% | -92.16% | -148.86% | -3,693.76% | -- |
| EBITDA | 71.86% | -18.42% | -45.24% | -2,897.06% | -- |
| EPS Basic | -121.28% | -331.58% | -69.44% | 14.78% | -- |
| Normalized Basic EPS | 55.17% | -47.06% | -72.73% | 16.67% | -- |
| EPS Diluted | -121.28% | -331.58% | -69.44% | 14.78% | -- |
| Normalized Diluted EPS | 55.17% | -47.06% | -72.73% | 16.67% | -- |
| Average Basic Shares Outstanding | 34.77% | 35.17% | 13.78% | 27.58% | -- |
| Average Diluted Shares Outstanding | 34.77% | 35.17% | 13.78% | 27.58% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |